Short report

PERTUSSIS IMMUNISATION IN PREGNANCY: A SUMMARY OF FUNDED AUSTRALIAN STATE AND TERRITORY PROGRAMS
Frank H Beard

Abstract

The Australian Immunisation Handbook, 10th edition now recommends pertussis vaccination during pregnancy as the preferred option for protecting vulnerable young infants. Jurisdictionally funded pertussis immunisation programs for pregnant women were progressively introduced in all Australian states and territories between August 2014 and June 2015. A meeting convened by the National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases was held on 31 May 2015 to share information regarding jurisdictional policies and program implementation. This report of that meeting provides the first published comparison of these jurisdictional programs, which are of a broadly similar nature but with important differences. Monitoring and evaluation of the uptake, safety and impact of the current programs in Australia will be important to inform future policy decisions. Commun Dis Intell 2015;39(3):E329–E336.

Keywords; immunisation programs; pertussis

Introduction

In 2013, the 10th edition of The Australian Immunisation Handbook included for the first time, the option of vaccinating pregnant women with pertussis vaccine in the 3rd trimester of pregnancy, rather than pre– or post-partum. These 3 options were presented as equivalent in terms of protecting infants, due to the absence of sufficient evidence to support any clear preference. Cocooning (vaccinating close contacts of infants, including parents, to reduce the likelihood of exposure) has been recommended in Australia since 2003 and some states and territories introduced funded cocoon programs in response to the recent pertussis epidemic. However, cocooning provides indirect protection and is only moderately effective. Following the publication of evidence showing that pertussis vaccination during pregnancy is both highly effective in preventing infant disease and safe, The Australian Immunisation Handbook was updated in March 2015 to clearly recommend pertussis vaccination during pregnancy as the preferred option, recommending optimal timing between 28 and 32 weeks gestation but that the vaccine can be given at any time during the 3rd trimester up to delivery.

Jurisdictionally funded pertussis immunisation programs for pregnant women have been progressively introduced in all Australian states and territories between August 2014 and June 2015. These programs are broadly similar in nature but with some differences in terms of policy and implementation.

A meeting, convened by the National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases (NCIRS), was held on 31 May 2015 immediately prior to the Communicable Disease Control Conference in Brisbane, aiming to share information regarding jurisdictional policies and program implementation, along with plans for evaluation of uptake, adverse events following immunisation, and disease impact. This meeting was attended by representatives from the Australian Government Department of Health and all 8 Australian states and territories except the Australian Capital Territory. This report summarises the key outcomes of this meeting and provides the first published summary of the commonalities and differences across jurisdictional programs and plans for evaluation.

Meeting outcomes

Program details

Commencement dates and implementation details for funded jurisdictional pertussis immunisation programs for pregnant women, along with whether any cocoon program is to be run simultaneously, are presented in the Table. Queensland was the first jurisdiction to introduce a program, commencing in August 2014, with all other jurisdictional programs introduced between March and June 2015.

All jurisdictions recommend vaccination from 28 weeks gestation and most note that 28–32 weeks is ideal. At the time of the meeting, Queensland
recommended vaccination only where no pertussis vaccine dose had been received in the last 5 years. However this was subsequently amended to accord with the updated *Australian Immunisation Handbook* recommendations (personal communication Scott Brown, Acting Manager, Immunisation Program, Department of Health, Queensland, 29 July 2015). Only 2 jurisdictions (Victoria and the Northern Territory) are funding a cocoon program in addition to their program for pregnant women.

**Implementation**

All jurisdictions provide vaccine via general practitioners and hospital antenatal clinics, with some also utilising Aboriginal medical services, local councils, community health centres, and obstetricians.

**Evaluation**

**Coverage assessment**

The most common plan for assessing vaccination coverage was through data from the relevant jurisdictional perinatal data collection (PDC). Vaccination during pregnancy will be captured on the Victorian and Queensland PDCs from July 2015 and on the New South Wales PDC at a state-wide level from January 2016. Some other jurisdictions reported attempts to organise inclusion on their PDC but a number of challenges were identified in achieving this. A range of alternative methods of coverage assessment were also planned, with the Northern Territory to use its own whole-of-life immunisation register and Western Australia an annual survey of a random sample of around 400 recently-delivered mothers.

Queensland advised an interim estimate of 40%–50% coverage as of May 2015, based on the number of births and consent forms returned centrally, and the use of a different brand of vaccine to that used in the adolescent school-based program allowing differentiation. Western Australia advised an interim estimate of around 55% coverage, based on the number of births in May 2015 and the number of forms returned by immunisation providers documenting administration of vaccine to pregnant women. Western Australia also reported that influenza vaccine coverage during pregnancy appeared to have improved as a result of the pertussis program, with the vaccines often co-administered.

**Vaccine safety**

Most jurisdictions reported that they will rely on existing (passive) surveillance systems for the reporting of adverse events following immunisation (AEFI). These involve reporting of AEFI by immunisation providers, and sometimes patients, with subsequent follow-up by public health agencies. In New South Wales this will be supplemented by emergency department syndromic surveillance while Western Australia will use active surveillance for AEFI with expansion of an SMS system used for AEFI monitoring for influenza vaccination during pregnancy.

**Disease impact/vaccine effectiveness**

Queensland, New South Wales and Western Australia reported the most advanced plans for evaluation of their respective programs. Queensland will evaluate vaccine effectiveness via a cohort study, linking data from their state-based immunisation register (Vaccination Information and Vaccination Administration System) with notifications database, perinatal data collection data, and birth registry data, while New South Wales will evaluate via a case-control study based on notified infant cases. Western Australia plans to expand its existing cohort study of influenza vaccine effectiveness during pregnancy to assess pertussis vaccine effectiveness, via linked midwives data collection, hospitalisation, notification and emergency department data, and data on vaccination in pregnancy reported by immunisation providers.

**Conclusions**

Currently, all available evidence supports vaccination during pregnancy as the best option for protecting vulnerable young infants from pertussis. Australia has high rates of pertussis, with high levels of hospitalisation (and occasional deaths) in young infants. Australian states and territories have taken the lead in implementing pertussis immunisation programs for pregnant women on the basis of this evidence and updated *Australian Immunisation Handbook* recommendations.

With broadly similar pertussis immunisation programs for pregnant women now in place and funded by all jurisdictions, for the first time in recent history Australia has immunisation programs that are implemented across the entire country that universally target a particular population but are outside the National Immunisation Program (NIP). This situation is likely to be of questionable sustainability. Since 2005 vaccines have been required to go through a standardised process of application to and assessment by the Pharmaceutical Benefits Advisory Committee (PBAC) for consideration of suitability and cost-effectiveness for funding under the NIP. It is currently unclear whether any vaccine manufacturer intends to submit an application
to the PBAC in regard to pertussis immunisation during pregnancy, and unclear what the outcome of such an application, if it eventuates, would be. Pertussis immunisation for pregnant women has been funded in national immunisation programs in the United Kingdom (though in the context of a temporary program with review after 5 years) and in New Zealand, and is recommended nationally by the Advisory Committee for Immunization Practices in the United States and ‘encouraged’ by the Public Health Agency of Canada. Monitoring and evaluation of the uptake, safety and impact of the current program arrangements in Australia will be important to inform future policy decisions.

Acknowledgements

The author would like to thank all the following attendees at the 31 May 2015 meeting for their attendance, contribution to the meeting, and subsequent comments on draft versions of this report: Vicky Sheppeard (NSW Health), Sonya Bennett (Department of Health, Queensland), Mark Veitch (Department of Health and Human Services, Tasmania), Finn Romanes (Department of Health and Human Services, Victoria), Rhonda Owen (Australian Government Department of Health), Nicolee Martin (Australian Government Department of Health), Megan Downie (Australian Government Department of Health), Anna Glynn-Robinson (Australian Government Department of Health), Stephen Lambert (University of Queensland/Department of Health, Queensland), Sarah Sheridan (University of Queensland), Louise Flood (Department for Health and Ageing, South Australia), Donna Mak (Health Department, Western Australia), Lauren Tracey (Health Department, Western Australia), Annette Regan (Health Department, Western Australia), Peter Markey (Department of Health, Northern Territory), Kerri Viney (Australian National University), Emily Fearnley (Australian National University), Rob Menzies (University of NSW), Kristine Macartney (NCIRS), Aditi Dey (NCIRS), Clayton Chiu (NCIRS).

The author would also like to thank jurisdictional members of the Communicable Diseases Network Australia for their support in ensuring appropriate attendance at the 31 May meeting, Rosalind Webby (Department of Health, Northern Territory) for comments on the report, Helen Quinn and Amy Vassallo (NCIRS) for assistance in identifying and summarising the relevant literature, and Peter McIntyre (NCIRS) for suggesting and conceptualising the meeting.

Author details

Dr Frank H Beard
1,2
1. National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases, The Children’s Hospital at Westmead, New South Wales
2. The University of Sydney, Sydney, New South Wales

Correspondence: Dr Frank Beard, Staff Specialist – Public Health Physician, National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases, Locked Bag 4001, WESTMEAD NSW 2145. Telephone: +61 2 9845 1423. Facsimile: +61 2 9845 1418. Email: frank.beard@health.nsw.gov.au
Table: Funded pregnancy/cocoon pertussis immunisation program implementation, by Australian states and territories (information as of 31 May 2015)

<table>
<thead>
<tr>
<th>State or territory</th>
<th>Australian Capital Territory*</th>
<th>New South Wales</th>
<th>Northern Territory</th>
<th>Queensland</th>
<th>South Australia</th>
<th>Tasmania</th>
<th>Victoria</th>
<th>Western Australia</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Program dates and details</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vaccine</td>
<td>Boostrix® and Adacel®</td>
<td>Boostrix®</td>
<td>Adacel® (cf adolescent program using Boostrix®)</td>
<td>Adacel® (cf adolescent program using Boostrix®)</td>
<td>Adacel® (cf adolescent program using Boostrix®)</td>
<td>Boostrix®</td>
<td>Boostrix® (cf adolescent program using Adacel®)</td>
<td>Boostrix® (cf adolescent program using Adacel®)</td>
</tr>
<tr>
<td><strong>Target group in terms of gestational age</strong></td>
<td>From 28 weeks gestation in each pregnancy (recommended at 28 weeks gestation or as soon as possible after that)</td>
<td>From 28 weeks gestation in each pregnancy (ideally 28–32 weeks)</td>
<td>From 28 weeks gestation, if have not had a pertussis containing vaccine in the last 5 years†</td>
<td>From 28 weeks gestation in each pregnancy (ideally 28–32 weeks)</td>
<td>From 28 weeks gestation in each pregnancy (ideally 28–32 weeks)</td>
<td>From 28 weeks gestation in each pregnancy (ideally 28–32 weeks)</td>
<td>From 28 weeks gestation in each pregnancy (ideally 28–32 weeks)</td>
<td>From 28 weeks gestation in each pregnancy (ideally 28–32 weeks)</td>
</tr>
<tr>
<td>Funded cocoon program?</td>
<td>No</td>
<td>No</td>
<td>Yes (since 2008 – currently targets fathers/carers in household of an infant under the age of 7 months – can be given from time expectant mother reaches 28 weeks gestation)</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>Yes (parents and guardians of infants up to 6 months of age and born on or after 1 June 2015, and partners of women who are at least 28 weeks pregnant, if they have not received a pertussis booster in the last 10 years)</td>
<td>No</td>
</tr>
</tbody>
</table>

**Implementation**

| Providers | GPs, antenatal clinics. | GPs, AMSs, antenatal clinics | All providers, majority in community health centres. Also GPs and antenatal clinics | Mainly GPs, also antenatal clinics and councils | Mainly GPs, also antenatal clinics and councils | GPs mainly, some in antenatal clinics | All providers – GPs, antenatal clinics and possibly councils | GPs, antenatal clinics and obstetricians |
### Table (cont’d): Funded pregnancy/cocoon pertussis immunisation program implementation, by Australian states and territories (information as of 31 May 2015)

<table>
<thead>
<tr>
<th>State or territory</th>
<th>Australian Capital Territory*</th>
<th>New South Wales</th>
<th>Northern Territory</th>
<th>Queensland</th>
<th>South Australia</th>
<th>Tasmania</th>
<th>Victoria</th>
<th>Western Australia</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Evaluation</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Coverage assessment</td>
<td>Via perinatal data collection (will be collected state-wide by 1 January 2016)</td>
<td>Northern Territory immunisation register</td>
<td>Use of Adacel® allows differentiation from adolescent program, also consent forms returned centrally</td>
<td>Not currently in perinatal data collection</td>
<td>Via perinatal data collection</td>
<td>Annual survey of a random sample of ~400 recently-delivered mothers (baseline coverage 5%)</td>
<td>Working to get pertussis vaccination into perinatal data collection</td>
<td>Coverage estimated at around 55%</td>
</tr>
<tr>
<td>Vaccine safety</td>
<td>Emergency department syndromic surveillance</td>
<td>Usual way</td>
<td>Follow-up of reported adverse events following pertussis-containing vaccine in women of child-bearing age; reviewed by expert advisory group</td>
<td>Usual way</td>
<td>Usual way</td>
<td>Usual way</td>
<td>Via SMS back system – expansion of existing system used for monitoring adverse events following influenza vaccination during pregnancy</td>
<td></td>
</tr>
<tr>
<td>Formal evaluation of impact/vaccine effectiveness</td>
<td>Case-control study of vaccine effectiveness, based on notified infant cases</td>
<td>Planning evaluation</td>
<td>Cohort study of vaccine effectiveness – linkage of data from state-based immunisation register with notifications database, perinatal data collection, and birth registry data</td>
<td>None planned, but will capture maternal vaccination status in all infant pertussis cases</td>
<td>None planned, but will capture maternal vaccination status in all infant pertussis cases</td>
<td>Scoping options</td>
<td>Aim to expand cohort study of influenza vaccine effectiveness during pregnancy to assess pertussis vaccine effectiveness – linkage of midwives data collection, hospitalisation, notification and emergency department data</td>
<td></td>
</tr>
</tbody>
</table>
Table (cont’d): Funded pregnancy/cocoon pertussis immunisation program implementation, by Australian states and territories (information as of 31 May 2015)

<table>
<thead>
<tr>
<th>State or territory</th>
<th>Australian Capital Territory*</th>
<th>New South Wales</th>
<th>Northern Territory</th>
<th>Queensland</th>
<th>South Australia</th>
<th>Tasmania</th>
<th>Victoria</th>
<th>Western Australia</th>
</tr>
</thead>
<tbody>
<tr>
<td>Relevant website links for jurisdictional programs</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antenatal Pertussis Vaccination Program General Practitioners &amp; Immunisation Providers Q&amp;A</td>
<td>NSW Health news</td>
<td>Immunisation Pertussis (Whooping cough)</td>
<td>Immunisation</td>
<td>Pregnant and breastfeeding women</td>
<td>Whooping cough vaccine in pregnancy program</td>
<td>Free whooping cough vaccine for pregnant women</td>
<td>Q&amp;A for health professionals - Parent’s whooping cough vaccine program</td>
<td>Healthy WA; Adult immunisation schedule</td>
</tr>
<tr>
<td>Protecting your newborn from whooping cough Q&amp;A</td>
<td>NSW Health Immunisation programs</td>
<td>Adult and Special Groups Vaccination Schedule</td>
<td>NSW Pertussis Control Program 2015</td>
<td>Whooping cough vaccine program for pregnant women</td>
<td>Diphtheria, tetanus and whooping cough combination vaccines</td>
<td>Department of Health and Human Services Bulletin board</td>
<td>Better Health Channel Whooping Cough</td>
<td>Healthy WA; Pertussis vaccine in pregnancy – what expectant mothers need to know</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Whooping cough vaccine program for pregnant women information sheet</td>
<td></td>
<td></td>
<td></td>
<td>Operational Directives and Information Circulars</td>
</tr>
</tbody>
</table>

GP = general practitioners
AMS = Aboriginal medical services
* Information sourced from ACT Health website
† Funded for use in third trimester of pregnancy from September 2013 but not the preferred option until April 2015
‡ Subsequently amended to accord with updated Australian Immunisation Handbook recommendations
References


